查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
液体活检诊断市场：依癌症、依用途、依标记、依地点、依产品、价格和数量预测 - 执行顾问指南，定制预测和分析（2024-2028）
市场调查报告书
商品编码
1472610

液体活检诊断市场：依癌症、依用途、依标记、依地点、依产品、价格和数量预测 - 执行顾问指南，定制预测和分析（2024-2028）

Liquid Biopsy Markets By Cancer, Usage, Biomarker, Place, & Product With Price And Volume Outlook. Including Executive and Consultant Guides and Customized Forecasting and Analysis 2024-2028
出版日期: | 出版商: Howe Sound Research | 英文 585 Pages | 商品交期: 最快1-2个工作天内

价格

使用体外血液检查鑑定癌症 DNA 正在彻底改变癌症诊断。这项技术为广泛使用癌症筛检测试提供了潜力。

该报告研究了全球液体活检诊断市场，并提供了市场概述，包括癌症、使用、标记物、位置、产品和参与市场的公司概况的趋势。

目录

第一章 市场引导

第二章介绍和市场定义

  • 什么是液体切片？
  • 定序革命
  • 市场定义
  • 调查方法
  • 观点：医疗保健和IVD产业

第 3 章市场概况

  • 市场进入组织
    • 学术研究所
    • 诊断测试开发人员
    • 仪器仪表供应商
    • 药品及试剂製造商
    • 病理学供应商
    • 独立临床实验室
    • 国家研究所
    • 医院实验室
    • 临床实验室
    • 审计机构
    • 认证机构
  • 活检的使用
  • 切片部位
  • 目前状态-切片分析
  • 癌症的证据 - 液体切片技术
  • 癌症治疗方案面临危险
  • 产业结构的影响

第四章 市场趋势

  • 增长动力
  • 生长抑制因素
  • 测量和自动化
  • 诊断技术开发

第五章液体切片的最新进展

第六章 主要公司简介

  • Admera Health, LLC
  • Abbott Laboratories
  • AccuraGen Inc.
  • Acuamark Diagnostics
  • Agilent
  • Amoy Diagnostics Co., Ltd.
  • Anchor Dx
  • ANGLE plc
  • Applied DNA Sciences
  • ARUP Laboratories
  • AVIVA Systems Biology
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter Diagnostics（Danaher）
  • Becton, Dickinson and Company
  • Berkley Lights
  • BGI Genomics Co. Ltd
  • BillionToOne
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc.
  • Biodesix Inc.
  • BioFluidica
  • Biolidics Ltd
  • bioMerieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Techne
  • Bioview
  • Burning Rock
  • Cardiff Oncology
  • CareDx
  • Caris Molecular Diagnostics
  • CellCarta
  • CellMax Life
  • Cepheid（Danaher）
  • Circulogene
  • Cizzle Biotech
  • Clearbridge Biomedics
  • Clinical Genomics
  • Cytolumina Technologies Corp.
  • Datar Cancer Genetics Limited
  • Diagnologix LLC
  • Dxcover
  • Element Biosciences
  • Enzo Biochem
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exact Sciences
  • Fluxion Biosciences（Cell Microsystems）
  • Freenome
  • Fyr Diagnostics
  • GeneFirst Ltd.
  • Genetron Holdings
  • GILUPI Nanomedizin
  • Guardant Health
  • HansaBiomed
  • Haystack Oncology（Quest Dx）
  • iCellate
  • ICON PLC
  • Illumina
  • Incell Dx
  • Inivata
  • INOVIQ
  • Invitae Corporation
  • J&J Innovative Medicine
  • Lucence Health
  • Lunglife AI Inc
  • MDNA Life SCIENCES, Inc.
  • MDx Health
  • Menarini Silicon Biosystems
  • Mesa Laboratories, Inc.
  • Millipore Sigma
  • Miltenyi Biotec
  • miR Scientific
  • Myriad Genetics
  • Nanostring
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • Novogene
  • On-Chip Biotechnologies
  • Oncocyte
  • OncoDNA
  • Oncimmune
  • Oxford Nanopore Technologies
  • PamGene
  • Panagene
  • Personalis
  • PGDx（Labcorp）
  • PrecisionMed
  • Predicine
  • Predictive Oncology
  • Prenetics
  • Promega
  • Qiagen
  • Rarecells SAS
  • RareCyte
  • Revvity
  • Roche Diagnostics
  • Saga Diagnostics
  • Screencell
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc.
  • Singular Genomics
  • Standard BioTools
  • Stilla Technologies
  • Superfluid Dx
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific
  • Todos Medical
  • Ultima Genomics
  • Veracyte
  • VolitionRX
  • Vortex Biosciences

第七章全球液体切片诊断市场

  • 依国家/地区划分的世界市场概览
  • 依癌症划分的全球市场概览
  • 依用途划分的全球市场概览
  • 依地点划分的全球市场概览
  • 依生物标誌物划分的全球市场概览
  • 依产品划分的全球市场概览

第八章全球液体活检诊断市场 - 依癌症分类

  • 乳腺癌
  • 大肠癌
  • 子宫颈癌
  • 肺癌
  • 前列腺癌
  • 其他

第九章全球液体活检诊断市场 - 依应用

  • 测试
  • 诊断
  • 治疗
  • 监视

第十章全球液体切片诊断市场－依地点

  • 医院实验室
  • 实验室服务
  • 门诊化验室
  • 其他

第十一章全球液体活检诊断市场 - 依标记

  • 循环肿瘤细胞
  • 游离DNA
  • 囊泡
  • 其他

第十二章全球液体活检诊断市场 - 依产品

  • 成套工具
  • 设备
  • 服务

第十三章附录

OVERVIEW:

The Screening, Diagnostic, Therapy Selection, Minimal Residual Disease and Screening Market Potential are all explored in this report. We look at Price and Volume Outlooks by type of cancer. This report provides detailed analysis.

Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology has created the possibility of widespread cancer screening tests.

The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. What Growth Phase is the market in? The impact on the health care industry is enormous. The report forecasts the market size looking out 5 years. In addition, the report looks at potential market sizes by country, by cancer and by the four types of usage: screening, diagnosis, therapy selection and recurrence monitoring.

The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate, Cervical, and Other Cancers as well as breakouts by Screening/Early Detection, Diagnostic, Therapy Monitoring and Recurrence Monitoring.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1. Market Guides

  • 1.1. Liquid Biopsy Market-Strategic Situation Analysis
  • 1.2. Guide for Executives, Marketing, Sales, and Business Development Staff
  • 1.3. Guide for Management Consultants and Investment Advisors

2. Introduction and Market Definition

  • 2.1. What is Liquid Biopsy?
  • 2.2. The Sequencing Revolution
  • 2.3. Market Definition
    • 2.3.1. Revenue Market Size
  • 2.4. Methodology
    • 2.4.1. Methodology
    • 2.4.2. Sources
    • 2.4.3. Authors
  • 2.5. Perspective: Healthcare and the IVD Industry
    • 2.5.1. Global Healthcare Spending
    • 2.5.2. Spending on Diagnostics
    • 2.5.3. Important Role of Insurance for Diagnostics

3. Market Overview

  • 3.1. Players in a Dynamic Market
    • 3.1.1. Academic Research Lab
    • 3.1.2. Diagnostic Test Developer
    • 3.1.3. Instrumentation Supplier
    • 3.1.4. Chemical/Reagent Supplier
    • 3.1.5. Pathology Supplier
    • 3.1.6. Independent Clinical Laboratory
    • 3.1.7. Public National/regional Laboratory
    • 3.1.8. Hospital Laboratory
    • 3.1.9. Physicians Office Lab (POLS)
    • 3.1.10. Audit Body
    • 3.1.11. Certification Body
  • 3.2. Using Biopsies
    • 3.2.1. Cancer
    • 3.2.2. Precancerous conditions
    • 3.2.3. Inflammatory conditions
  • 3.3. Biopsy Sites
  • 3.4. The Situation Today-Biopsy Analysis
  • 3.5. Evidence of Cancer-Liquid Biopsy Technology
    • 3.5.1. The Big Picture on Liquid Biopsy Technology
    • 3.5.2. The Role of CTCs
    • 3.5.3. Application of CTCs
    • 3.5.4. CellSearch Detection- Ultimate Sensitivity
    • 3.5.5. Epic Sciences Detection- Imaging Takes the Lead
    • 3.5.6. Maintrac Detection-The Microscope
    • 3.5.7. Other Methods
    • 3.5.8. ctDNA Role
    • 3.5.9. ctDNA Applications
    • 3.5.10. Exosomes and Micro Vesicles-New Kid on the Block
    • 3.5.11. The Multiple Play
  • 3.6. Cancer Treatment Protocol Under Siege
    • 3.6.1. Issues to Liquid Biopsy Adoption-Double Diagnostics
    • 3.6.2. The Cancer Screening Market Opportunity
      • 3.6.2.1. GRAIL-What Is It?
    • 3.6.3. Cancer Management vs. Diagnosis
      • 3.6.3.1. The Role of Risk Assessment
      • 3.6.3.2. Managing Therapy
      • 3.6.3.3. Monitoring Disease-What Is It?
    • 3.6.4. Phases of Adoption-Looking into The Future
    • 3.6.5. The Promise of Liquid Biopsy
  • 3.7. Structure of Industry Plays a Part
    • 3.7.1. Hospital Testing Share
    • 3.7.2. Economies of Scale
      • 3.7.2.1. Hospital vs. Central Lab
    • 3.7.3. Physician Office Lab's
    • 3.7.4. Physician's and POCT

4. Market Trends

  • 4.1. Factors Driving Growth
    • 4.1.1. Non-Invasive Game Changer
    • 4.1.2. Lower Cost
    • 4.1.3. Greater Accuracy
    • 4.1.4. Wide Range of Potential Uses
    • 4.1.5. Aging Population
  • 4.2. Factors Limiting Growth
    • 4.2.1. Lower prices
    • 4.2.2. Lack of Standards
    • 4.2.3. Protocol Resistance
    • 4.2.4. Initial Adoption Cost
    • 4.2.5. Conclusion
  • 4.3. Instrumentation and Automation
    • 4.3.1. Instruments Key to Market Share
    • 4.3.2. Bioinformatics Plays a Role
  • 4.4. Diagnostic Technology Development
    • 4.4.1. Next Generation Sequencing Fuels a Revolution
    • 4.4.2. Impact of NGS on pricing
    • 4.4.3. Pharmacogenomics Blurs Diagnosis and Treatment
    • 4.4.4. CGES Testing, A Brave New World
    • 4.4.5. Biochips/Giant magneto resistance based assay

5. Liquid Biopsy Recent Developments

  • 5.1. Recent Developments-Importance and How to Use This Section
    • 5.1.1. Importance of These Developments
    • 5.1.2. How to Use This Section
  • 5.2. Delfi Dx Liquid Biopsy Technology Shows Promise
  • 5.3. Thermo Fisher Scientific, Bayer to Develop NGS-Based CDx
  • 5.4. Grail Details TBE Method for Cancer Monitoring
  • 5.5. Naveris HPV Liquid Biopsy Test Gets Medicare Coverage
  • 5.6. Personalis NeXT Personal Dx Early-Access Program
  • 5.7. Liquid Biopsy Shortens Time to Treatment
  • 5.8. Guardant Health MRD Test Garners Coverage
  • 5.9. IMBdx, AstraZeneca Expand Prostate Cancer Liquid Biopsy Partnership
  • 5.10. FoundationOne Liquid Biopsy Assay Gets FDA OK as Companion Diagnostic
  • 5.11. Epic Sciences Raises $24M for Breast Cancer Liquid Biopsy Test
  • 5.12. GenoMe Diagnostics Preparing DPCR-Based Ovarian Cancer Test
  • 5.13. Sophia Genetics to Commercialize Liquid Biopsy Test
  • 5.14. Agilent, Qiagen Nab FDA Approvals for Lung Cancer Treatment CDx
  • 5.15. Liquid Biopsy Startup Haystack Oncology Raises $56M
  • 5.16. Hedera Dx to Launch Liquid Biopsy Streamlined Platform
  • 5.17. PamGene Expanding Liquid Biopsy Assays
  • 5.18. Liquid Biopsy Firm Hedera Dx Raises Euro-14M
  • 5.19. MDxHealth Plans One-Stop Shop for Prostate Cancer Dx
  • 5.20. Precision Oncology Dx Access Varies Widely in Europe
  • 5.21. Extracellular Vesicles Show Promise as Early-Stage Cancer Diagnostic
  • 5.22. Predicine Receives CE Mark for Blood and Urine Liquid Biopsy
  • 5.23. BillionToOne Launches First Liquid Biopsy Products
  • 5.24. Dxcover Advances Multicancer Detection Platform
  • 5.25. CorePath Laboratories, Cizzle Biotechnology Partner on Lung Cancer Blood Test
  • 5.26. Illumina Sues Guardant Health Over Patents
  • 5.27. Invitae to Expand Cancer Testing Portfolio
  • 5.28. Cancer Centre, Inivata Partner on Clinical Liquid Biopsy Studies
  • 5.29. IVBH Bio Takes Aim at With Liquid Biopsy Incubator
  • 5.30. Molecular Health, Eone-Diagnomics Ink Liquid Biopsy Partnership
  • 5.31. Delfi Diagnostics Looks To Fragmentation-Based Liquid Biopsy Tech
  • 5.32. BillionToOne Adapting Fetal Dx Tech for Liquid Biopsy
  • 5.33. EDGC to Expand Liquid Biopsy Space With Cell-Free DNA Platform
  • 5.34. Liquid Biopsy Startup BioCaptiva Raises Pound-1M in Seed Funding
  • 5.35. Agilent Enters Liquid Biopsy Market with Resolution Biosciences Acquisition
  • 5.36. Bio-Techne to Acquire Asuragen for up to $320M
  • 5.37. Personalis Broadens Liquid Biopsy Offering
  • 5.38. Exact Sciences to Offer End-to-End Cancer Testing With Ashion Acquisition
  • 5.39. Delfi Diagnostics Plans Multi-Cancer Screening Test
  • 5.40. Menarini's CellSearch Shows Potential to Predict Breast Cancer Prognosis, Treatment Response
  • 5.41. Liquid Biopsy NGS Panels-Diverse Test Claims
  • 5.42. CMS Colon Cancer Screening Memo Bodes Well for Assays
  • 5.43. Natera Liquid Biopsy Test Coverage to Expand
  • 5.44. Freenome Closes Financing to Support Early Cancer Detection Trial
  • 5.45. C$2.6M Liquid Biopsy Initiative
  • 5.46. NeoGenomics, Inivata Partner for Lung Cancer Liquid Biopsy
  • 5.47. Liquid Biopsy Shows Promise as Screen for Cancers
  • 5.48. Inivata launches RaDaR(TM) for the detection of residual disease and recurrence
  • 5.49. Liquid Biopsy Assay Detects 50+ Types of Cancer
  • 5.50. Liquid Biopsy Study Confirms Concordance with Tissue Biopsy

6. Profiles of Key Players

  • 6.1. Admera Health, LLC
  • 6.2. Abbott Laboratories
  • 6.3. AccuraGen Inc.
  • 6.4. Acuamark Diagnostics
  • 6.5. Agilent
  • 6.6. Amoy Diagnostics Co., Ltd.
  • 6.7. Anchor Dx
  • 6.8. ANGLE plc
  • 6.9. Applied DNA Sciences
  • 6.10. ARUP Laboratories
  • 6.11. AVIVA Systems Biology
  • 6.12. Baylor Miraca Genetics Laboratories
  • 6.13. Beckman Coulter Diagnostics (Danaher)
  • 6.14. Becton, Dickinson and Company
  • 6.15. Berkley Lights
  • 6.16. BGI Genomics Co. Ltd
  • 6.17. BillionToOne
  • 6.18. Bioarray Genetics
  • 6.19. Biocartis
  • 6.20. Biocept, Inc.
  • 6.21. Biodesix Inc.
  • 6.22. BioFluidica
  • 6.23. Biolidics Ltd
  • 6.24. bioMerieux Diagnostics
  • 6.25. Bioneer Corporation
  • 6.26. Bio-Rad Laboratories, Inc
  • 6.27. Bio-Techne
  • 6.28. Bioview
  • 6.29. Burning Rock
  • 6.30. Cardiff Oncology
  • 6.31. CareDx
  • 6.32. Caris Molecular Diagnostics
  • 6.33. CellCarta
  • 6.34. CellMax Life
  • 6.35. Cepheid (Danaher)
  • 6.36. Circulogene
  • 6.37. Cizzle Biotech
  • 6.38. Clearbridge Biomedics
  • 6.39. Clinical Genomics
  • 6.40. Cytolumina Technologies Corp.
  • 6.41. Datar Cancer Genetics Limited
  • 6.42. Diagnologix LLC
  • 6.43. Dxcover
  • 6.44. Element Biosciences
  • 6.45. Enzo Biochem
  • 6.46. Epic Sciences
  • 6.47. Epigenomics AG
  • 6.48. Eurofins Scientific
  • 6.49. Exact Sciences
  • 6.50. Fluxion Biosciences (Cell Microsystems)
  • 6.51. Freenome
  • 6.52. Fyr Diagnostics
  • 6.53. GeneFirst Ltd.
  • 6.54. Genetron Holdings
  • 6.55. GILUPI Nanomedizin
  • 6.56. Guardant Health
  • 6.57. HansaBiomed
  • 6.58. Haystack Oncology (Quest Dx)
  • 6.59. iCellate
  • 6.60. ICON PLC
  • 6.61. Illumina
  • 6.62. Incell Dx
  • 6.63. Inivata
  • 6.64. INOVIQ
  • 6.65. Invitae Corporation
  • 6.66. J&J Innovative Medicine
  • 6.67. Lucence Health
  • 6.68. Lunglife AI Inc
  • 6.69. MDNA Life SCIENCES, Inc.
  • 6.70. MDx Health
  • 6.71. Menarini Silicon Biosystems
  • 6.72. Mesa Laboratories, Inc.
  • 6.73. Millipore Sigma
  • 6.74. Miltenyi Biotec
  • 6.75. miR Scientific
  • 6.76. Myriad Genetics
  • 6.77. Nanostring
  • 6.78. NantHealth, Inc.
  • 6.79. Natera
  • 6.80. NeoGenomics
  • 6.81. Novogene
  • 6.82. On-Chip Biotechnologies
  • 6.83. Oncocyte
  • 6.84. OncoDNA
  • 6.85. Oncimmune
  • 6.86. Oxford Nanopore Technologies
  • 6.87. PamGene
  • 6.88. Panagene
  • 6.89. Personalis
  • 6.90. PGDx (Labcorp)
  • 6.91. PrecisionMed
  • 6.92. Predicine
  • 6.93. Predictive Oncology
  • 6.94. Prenetics
  • 6.95. Promega
  • 6.96. Qiagen
  • 6.97. Rarecells SAS
  • 6.98. RareCyte
  • 6.99. Revvity
  • 6.100. Roche Diagnostics
  • 6.101. Saga Diagnostics
  • 6.102. Screencell
  • 6.103. Siemens Healthineers
  • 6.104. simfo GmbH
  • 6.105. Singlera Genomics Inc.
  • 6.106. Singular Genomics
  • 6.107. Standard BioTools
  • 6.108. Stilla Technologies
  • 6.109. Superfluid Dx
  • 6.110. Sysmex Inostics
  • 6.111. Tempus Labs, Inc.
  • 6.112. Thermo Fisher Scientific
  • 6.113. Todos Medical
  • 6.114. Ultima Genomics
  • 6.115. Veracyte
  • 6.116. VolitionRX
  • 6.117. Vortex Biosciences

7. The Global Market for Liquid Biopsy Diagnostics

  • 7.1. Global Market Overview by Country
    • 7.1.1. Table-Global Market by Country
    • 7.1.2. Chart-Global Market by Country
  • 7.2. Global Market by Cancer-Overview
    • 7.2.1. Table-Global Market by Cancer
    • 7.2.2. Chart-Global Market by Cancer-Base/Final Year Comparison
    • 7.2.3. Chart-Global Market by Cancer-Base Year
    • 7.2.4. Chart-Global Market by Cancer-End Year
    • 7.2.5. Chart-Global Market by Cancer-Share by Year
    • 7.2.6. Chart-Global Market by Cancer-Segments Growth
  • 7.3. Global Market by Usage-Overview
    • 7.3.1. Table-Global Market by Usage
    • 7.3.2. Chart-Global Market by Usage-Base/Final Year Comparison
    • 7.3.3. Chart-Global Market by Usage-Base Year
    • 7.3.4. Chart-Global Market by Usage-End Year
    • 7.3.5. Chart-Global Market by Usage-Share by Year
    • 7.3.6. Chart-Global Market by Usage-Segments Growth
  • 7.4. Global Market by Place-Overview
    • 7.4.1. Table-Global Market by Place
    • 7.4.2. Chart-Global Market by Place-Base/Final Year Comparison
    • 7.4.3. Chart-Global Market by Place-Base Year
    • 7.4.4. Chart-Global Market by Place-End Year
    • 7.4.5. Chart-Global Market by Place-Share by Year
    • 7.4.6. Chart-Global Market by Place-Segments Growth
  • 7.5. Global Market by Marker-Overview
    • 7.5.1. Table-Global Market by Marker
    • 7.5.2. Chart-Global Market by Marker-Base/Final Year Comparison
    • 7.5.3. Chart-Global Market by Marker-Base Year
    • 7.5.4. Chart-Global Market by Marker-End Year
    • 7.5.5. Chart-Global Market by Marker-Share by Year
    • 7.5.6. Chart-Global Market by Marker-Segments Growth
  • 7.6. Global Market by Product-Overview
    • 7.6.1. Table-Global Market by Product
    • 7.6.2. Chart-Global Market by Product-Base/Final Year Comparison
    • 7.6.3. Chart-Global Market by Product-Base Year
    • 7.6.4. Chart-Global Market by Product-End Year
    • 7.6.5. Chart-Global Market by Product-Share by Year
    • 7.6.6. Chart-Global Market by Product-Segments Growth

8. Global Liquid Biopsy Diagnostic Markets-By Cancer

  • 8.1. Breast
    • 8.1.1. Table Breast-by Country
    • 8.1.2. Table Breast-by Country, Price
    • 8.1.3. Table Breast-by Country Volume
    • 8.1.4. Chart-Breast Growth
  • 8.2. Colorectal
    • 8.2.1. Table Colorectal-by Country
    • 8.2.2. Table Colorectal-by Country, Price
    • 8.2.3. Table Colorectal-by Country, Volume
    • 8.2.4. Chart-Colorectal Growth
  • 8.3. Cervical
    • 8.3.1. Table Cervical-by Country
    • 8.3.2. Table Cervical-by Country, Price
    • 8.3.3. Table Cervical-by Country, Volume
    • 8.3.4. Chart-Cervical Growth
  • 8.4. Lung
    • 8.4.1. Table Lung-by Country
    • 8.4.2. Table Lung-by Country, Price
    • 8.4.3. Table Lung-by Country, Volume
    • 8.4.4. Chart-Lung Growth
  • 8.5. Prostate
    • 8.5.1. Table Prostate-by Country
    • 8.5.2. Table Prostate-by Country, Price
    • 8.5.3. Table Prostate-by Country, Volume
    • 8.5.4. Chart-Prostate Growth
  • 8.6. Other
    • 8.6.1. Table Other-by Country
    • 8.6.2. Table Other-by Country, Price
    • 8.6.3. Table Other-by Country, Volume
    • 8.6.4. Chart-Other Growth

9. Global Liquid Biopsy Diagnostic Markets-by Usage

  • 9.1. Screening
    • 9.1.1. Table Screening-by Country
  • 9.2. Chart-Screening Growth
  • 9.3. Diagnostic
    • 9.3.1. Table Diagnostic-by Country
    • 9.3.2. Chart-Diagnostic Growth
  • 9.4. Therapy
    • 9.4.1. Table Therapy-by Country
    • 9.4.2. Chart-Therapy Growth
  • 9.5. Monitor
    • 9.5.1. Table Monitor-by Country
    • 9.5.2. Chart-Monitor Growth

10. Global Liquid Biopsy Diagnostic Markets-by Place

  • 10.1. Hospital Lab
    • 10.1.1. Table Hospital Lab-by Country
    • 10.1.2. Chart-Hospital Lab Growth
  • 10.2. Lab Service
    • 10.2.1. Table Lab Service-by Country
    • 10.2.2. Chart-Lab Service Growth
  • 10.3. Lab Outpatient
    • 10.3.1. Table Lab Outpatient-by Country
    • 10.3.2. Chart-Lab Outpatient Growth
  • 10.4. Other Lab
    • 10.4.1. Table Other Lab-by Country
    • 10.4.2. Chart-Other Lab Growth

11. Global Liquid Biopsy Diagnostic Markets-by Marker

  • 11.1. Circulating Tumor Cell
    • 11.1.1. Table Circulating Tumor Cell-by Country
    • 11.1.2. Chart-Circulating Tumor Cell Growth
  • 11.2. Cell Free DNA
    • 11.2.1. Table Cell Free DNA-by Country
    • 11.2.2. Chart-Cell Free DNA Growth
  • 11.3. Vesicle
    • 11.3.1. Table Vesicle-by Country
    • 11.3.2. Chart-Vesicle Growth
  • 11.4. Other Marker
    • 11.4.1. Table Other Marker-by Country
    • 11.4.2. Chart-Other Marker Growth

12. Global Liquid Biopsy Diagnostic Markets-by Product

  • 12.1. Kits
    • 12.1.1. Table Kits-by Country
    • 12.1.2. Chart-Kits Growth
  • 12.2. Instruments
    • 12.2.1. Table Instruments-by Country
    • 12.2.2. Chart-Instruments Growth
  • 12.3. Service
    • 12.3.1. Table Service-by Country
    • 12.3.2. Chart-Service Growth

13. Appendices

  • 13.1. Growth of Approved IVD Test Menu
  • 13.2. Growth of Approved Average IVD Test Fee
  • 13.3. The Most Used IVD Assays
  • 13.4. The Highest Grossing Assays
  • 13.5. Laboratory Fees Schedule

Table of Tables

  • Table 1: Market Players by Type
  • Table 2: Biopsy Sites
  • Table 3: LB Clinical Applications by Entity
  • Table 4: Advantages of Liquid Biopsy in Screening Market
  • Table 5: Outlook-Phases of Liquid Biopsy Adoption by Year
  • Table 6: Five Factors Driving Growth
  • Table 7: Factors Limiting Growth
  • Table 8: Key Diagnostic Laboratory Technology Trends
  • Table 9: Next Generation Sequencing Technologies-Speed and Cost
  • Table 10-Global Market by Region
  • Table 11: Global Market by Cancer
  • Table 12: Global Market by Usage
  • Table 13: Global Market by Place
  • Table 14: Global Market by Marker
  • Table 15: Global Market by Product
  • Table 16: Breast by Country
  • Table 17: Breast by Country Price
  • Table 18: Breast by Country Volume
  • Table 19: Colorectal by Country
  • Table 20: Colorectal by Country Price
  • Table 21: Colorectal by Country Volume
  • Table 22: Cervical by Country
  • Table 23: Cervical by Country Price
  • Table 24: Cervical by Country Volume
  • Table 25: Lung by Country
  • Table 26: Lung by Country Price
  • Table 27: Lung by Country Volume
  • Table 28: Prostate by Country
  • Table 29: Prostate by Country Price
  • Table 30: Prostate by Country Volume
  • Table 31: Other by Country
  • Table 32: Other by Country Price
  • Table 33: Other by Country Volume
  • Table 34: Screening by Country
  • Table 35: Diagnostic by Country
  • Table 36: Therapy by Country
  • Table 37: Monitor by Country
  • Table 38: Hospital Lab by Country
  • Table 39: Lab Service by Country
  • Table 40: Lab Outpatient by Country
  • Table 41: Other Lab by Country
  • Table 42: Circulating Tumor Cell by Country
  • Table 43: Cell Free DNA by Country
  • Table 44: Vesicle by Country
  • Table 45: Other Marker by Country
  • Table 46: Kits by Country
  • Table 47: Instruments by Country
  • Table 48: Service by Country
  • Table 49: The Most Common Assays
  • Table 50: Largest Revenue Assays
  • Table 51: Clinical Lab Fee Schedule

Table of Figures

  • Figure 1: Global Healthcare Spending Picture
  • Figure 2: The Global Lab Test Pie
  • Figure 3: The Road to Diagnostics
  • Figure 4: Comparison of Liquid vs Tissue Biopsy
  • Figure 5: Entities Analyzed in liquid Biopsy
  • Figure 6: Characteristics of Different Vesicle Types
  • Figure 7: The Changing Age of World Population
  • Figure 8: Health Care Consumption by Age
  • Figure 9: Cancer Incidence-Age at Diagnosis
  • Figure 10: Global Market Regional Share Chart
  • Figure 11: Global Market by Cancer-Base vs. Final
  • Figure 12: Global Market by Cancer Base Year
  • Figure 13: Global Market by Cancer End Year
  • Figure 14: Cancer Share by Year
  • Figure 15: Cancer Segments Growth
  • Figure 16: Global Market by Usage-Base vs. Final
  • Figure 17: Global Market by Usage Base Year
  • Figure 18: Global Market by Usage End Year
  • Figure 19: Usage Share by Year
  • Figure 20: Usage Segments Growth
  • Figure 21: Global Market by Place-Base vs. Final
  • Figure 22: Global Market by Place Base Year
  • Figure 23: Global Market by Place End Year
  • Figure 24: Place Share by Year
  • Figure 25: Place Segments Growth
  • Figure 26: Global Market by Marker-Base vs. Final
  • Figure 27: Global Market by Marker Base Year
  • Figure 28: Global Market by Marker End Year
  • Figure 29: Marker Share by Year
  • Figure 30: Marker Segments Growth
  • Figure 31: Global Market by Product-Base vs. Final
  • Figure 32: Global Market by Product Base Year
  • Figure 33: Global Market by Product End Year
  • Figure 34: Product Share by Year
  • Figure 35: Product Segments Growth
  • Figure 36: Breast Growth
  • Figure 37: Colorectal Diagnostics Growth
  • Figure 38: Cervical Growth
  • Figure 39: Lung Growth
  • Figure 40: Prostate Growth
  • Figure 41: Other Growth
  • Figure 42: Screening Growth
  • Figure 43: Diagnostic Growth
  • Figure 44: Therapy Growth
  • Figure 45: Monitor Growth
  • Figure 46: Hospital Lab Growth
  • Figure 47: Lab Service Growth
  • Figure 48: Lab Outpatient Growth
  • Figure 49: Other Lab Growth
  • Figure 50: Circulating Tumor Cell Growth
  • Figure 51: Cell Free DNA Growth
  • Figure 52: Vesicle Growth
  • Figure 53: Other Marker Growth
  • Figure 54: Kits Growth
  • Figure 55: Instruments Growth
  • Figure 56: Service Growth
  • Figure 57: IVD Test Menu Growth
  • Figure 58: IVD Test Average Fees-A Ten Year View